AIDS-related malignant lymphoma: results of prospective treatment trials

• Published in: Journal of clinical oncology Vol. 5; no. 9; p. 1322
• Main Authors: Gill, P S, Levine, A M, Krailo, M, Rarick, M U, Loureiro, C, Deyton, L, Meyer, P, Rasheed, S
• Format: Journal Article
• Language: English
• Published: United States 01.09.1987
• Subjects: Acquired Immunodeficiency Syndrome - complications; Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Asparaginase - administration & dosage; B-Lymphocytes; Bleomycin - administration & dosage; Cyclophosphamide - administration & dosage; Cytarabine - administration & dosage; Dexamethasone - administration & dosage; Doxorubicin - administration & dosage; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leucovorin - administration & dosage; Lymphoma - drug therapy; Lymphoma - etiology; Male; Methotrexate - administration & dosage; Middle Aged; Prednisone - administration & dosage; Prospective Studies; Vincristine - administration & dosage
• ISSN: 0732-183X
• DOI: 10.1200/JCO.1987.5.9.1322

Twenty-two consecutive patients with high-grade, B-cell lymphomas related to the acquired immunodeficiency syndrome (AIDS) were accrued onto two sequential phase II studies, consisting of a standard regimen (M-BACOD, group no. 1, N = 13), or a novel, intensive regimen (group no. 2, N = 9), which included high-dose cytosine arabinoside (HD-Ara-C), and high-dose methotrexate (HD-MTX), in an attempt to prevent CNS relapse and improve response rates. Stage IV disease was present in 82%. Complete remission (CR) was achieved in seven of 13 patients (54%) in group no. 1, and in three of nine (33%) group no. 2 (P = NS). By multivariate analysis, the most significant factor in predicting response was a Karnofsky performance score (KPS) greater than 60 (P = .04). Three of the ten patients who achieved CR on either regimen have relapsed; in all, five of 13 patients (31%) in group no. 1 have achieved disease-free survival for more than 1 year, compared with one of nine (11%) in group no. 2. CNS progression occurred in six patients in group no. 2, and in two patients in group no. 1. Hematologic toxicity was significantly greater in group no. 2, and these patients had an increased risk of opportunistic infection (one in group no. 1 v seven in group no. 2; P less than .01). Survival was similar, with a median of 11 months in group no. 1 and 6 months in group no. 2. We conclude that the intensive regimen of combination chemotherapy described here is associated with significant risk of early death due to opportunistic infection in patients with AIDS-related lymphoma, and that progression in the CNS remains a major problem. Trials of combination chemotherapy of a less intensive nature, perhaps in combination with immunomodulators or antiretroviral agents should be explored.